This biotech startup wants to delay menopause within 15 years

This site may earn authorized commissions from links on this page. Terms of use.

(Photo: Dingjeu Li / Unsplash)
Menopause is no joke. Between hot flashes, sleep problems, chills, seemingly irrational mood swings, and associated health risks, this period of a person’s life is inconvenient for some and tragic for others. Biotech startup Selmatics hopes to change that. CEO Piraye Beim, who founded Selmatics In 2009, it was working to develop a drug that could effectively delay menopause, giving patients a few more years of symptom-free life.

Menopause begins when someone’s ovaries produce much less estrogen and progesterone than before. This slows down the secretion of ovarian follicles which affects one’s fertility. Although everyone hits menopause at a slightly different pace, Beim believes he and his firm can offset the onset of this stage between 10 and 15 years, pushing the average onset age to 70 years. This will both increase the patient’s fertility and prevent health problems associated with the onset of menopause, such as heart disease, bone disease and Alzheimer’s.

“If we can buy women an additional 10 to 15 years of natural endocrine function, we are talking about a huge increase in their vitality and their well-being at a critical stage in their lives,” Beim said. To say Luckily when Selmatics ’mission came to light last year. Selmatics plans to begin clinical trials of its menopausal drug in 2023. Trials will begin with women’s chemotherapy, a common cause of premature menopause.

(Photo: Louis Reid / Unsplash)

The drug Selmatics works primarily by mimicking the anti-mullerian hormone (AMH), which produces ovarian follicles to normally regulate the body’s reproductive function. Patients will be able to stop taking the drug if they want to have children, just as they already have birth control. Selmatics is also working to experiment with new non-hormonal contraceptives under a grant from the Bill and Melinda Gates Foundation, as hormone alternatives bring with them many side effects that make most contraceptives attractive.

Healthcare options that primarily affect women have not been studied for a long time and have been under-funded for reasons we won’t go here, but beam is seeing big changes on the horizon. Selmatics has been working with Bayer, a multinational pharmaceutical and life science company, since 2020, which has poured millions of dollars into women’s healthcare research in recent years. Increase Awareness With the rise of women’s health issues, the rise of “femtech” (a medical technology focused on women delivered at birth) is helping medical professionals take their patients’ experiences more seriously.

Read now:

Leave a Reply

Your email address will not be published.